Causes and Consequences of Persistent Anemia After 6 Months of Antiretroviral Therapy in Tanzania: An Observational Comparative Cohort Study

Overview

Journal Am J Trop Med Hyg

Specialty Tropical Medicine

Date 2024 Oct 29

PMID 39471500

Authors

Duncan K Hau

Salama Fadhil

Myung Hee Lee

Bernard Desderius

Megan Willkens

Samuel E Kalluvya

Erius Tebuka

Luke R Smart

Robert N Peck

Affiliations

Soon will be listed here.

Abstract

Anemia is common among people living with HIV (PLWH), particularly in Africa. Outcomes for PLWH on modern antiretroviral therapy (ART) regimens are not well documented. We conducted an observational study to determine the outcomes and predictors of anemia after ART initiation in Tanzania. We enrolled and followed ART-naïve PLWH and HIV-uninfected individuals at three clinics in Tanzania. We grouped participants into four longitudinal categories based on hemoglobin concentration measured at baseline and 6 months after ART initiation (normal, resolved anemia, incident anemia, and persistent anemia) and followed them for 24 months. There were 991 study participants (494 PLWH, 497 HIV uninfected). After 6 months of ART, 33.9% of PLWH had persistent anemia and 9.9% had incident anemia compared with 12.6% and 9.6% for HIV-uninfected controls. Female sex (adjusted odds ratio [aOR]: 2.62; 95% CI: 1.91-6.75) and low income (aOR: 3.10; 95% CI: 1.36-7.20) were strong predictors of persistent anemia for both PLWH and HIV-uninfected individuals. For PLWH, having a CD4+ T cell count of less than 350 cells/mm3 (aOR: 0.34; 95% Cl: 0.15-0.73) was significantly associated with anemia resolution. Mortality was higher for PLWH who had persistent anemia or incident anemia than for PLWH who had normal hemoglobin or improved anemia (hazard ratio: 4.0, 95% Cl 1.3-12.2). One-third of adults in Tanzania had persistent anemia after 6 months on ART, and persistent anemia was associated with increased mortality. PLWH with persistent or incident anemia after 6 months on modern ART deserve close follow-up, particularly women and low-income adults.

References

Ezeamama A, Guwatudde D, Sikorskii A, Kabagambe E, Spelts R, Vahey G . Impaired Hematologic Status in Relation to Clinical Outcomes among HIV-Infected Adults from Uganda: A Prospective Cohort Study. Nutrients. 2018; 10(4). PMC: 5946260. DOI: 10.3390/nu10040475. View

Getaneh Z, Wale W, Chanie B, Temesgen E, Abebe M, Walie M . Magnitude and associated factors of anemia among AZT based HAART experienced adult HIV patients at University of Gondar Comprehensive Specialized Referral Hospital, Northwest, Ethiopia, 2019: a retrospective cohort study. BMC Infect Dis. 2021; 21(1):1016. PMC: 8480035. DOI: 10.1186/s12879-021-06712-5. View

Moh R, Danel C, Sorho S, Sauvageot D, Anzian A, Minga A . Haematological changes in adults receiving a zidovudine-containing HAART regimen in combination with cotrimoxazole in Côte d'Ivoire. Antivir Ther. 2005; 10(5):615-24. DOI: 10.1177/135965350501000510. View

Gunda D, Kilonzo S, Mpondo B . Magnitude and correlates of moderate to severe anemia among adult HIV patients receiving first line HAART in Northwestern Tanzania: a cross sectional clinic based study. Pan Afr Med J. 2016; 23:26. PMC: 4856498. DOI: 10.11604/pamj.2016.23.26.8268. View

Belperio P, Rhew D . Prevalence and outcomes of anemia in individuals with human immunodeficiency virus: a systematic review of the literature. Am J Med. 2004; 116 Suppl 7A:27S-43S. DOI: 10.1016/j.amjmed.2003.12.010. View

Abioye A, Andersen C, Sudfeld C, Fawzi W . Anemia, Iron Status, and HIV: A Systematic Review of the Evidence. Adv Nutr. 2020; 11(5):1334-1363. PMC: 7490171. DOI: 10.1093/advances/nmaa037. View

Clark T, Semba R . Iron supplementation during human immunodeficiency virus infection: a double-edged sword?. Med Hypotheses. 2001; 57(4):476-9. DOI: 10.1054/mehy.2001.1368. View

Marchionatti A, Parisi M . Anemia and thrombocytopenia in people living with HIV/AIDS: a narrative literature review. Int Health. 2020; 13(2):98-109. PMC: 7902680. DOI: 10.1093/inthealth/ihaa036. View

Johannessen A, Naman E, Gundersen S, Bruun J . Antiretroviral treatment reverses HIV-associated anemia in rural Tanzania. BMC Infect Dis. 2011; 11:190. PMC: 3145581. DOI: 10.1186/1471-2334-11-190. View

10.

Peck R, Shedafa R, Kalluvya S, Downs J, Todd J, Suthanthiran M . Hypertension, kidney disease, HIV and antiretroviral therapy among Tanzanian adults: a cross-sectional study. BMC Med. 2014; 12:125. PMC: 4243281. DOI: 10.1186/s12916-014-0125-2. View

11.

Kavishe B, Biraro S, Baisley K, Vanobberghen F, Kapiga S, Munderi P . High prevalence of hypertension and of risk factors for non-communicable diseases (NCDs): a population based cross-sectional survey of NCDS and HIV infection in Northwestern Tanzania and Southern Uganda. BMC Med. 2015; 13:126. PMC: 4476208. DOI: 10.1186/s12916-015-0357-9. View

12.

Akilimali P, Kashala-Abotnes E, Musumari P, Kayembe P, Tylleskar T, Mapatano M . Predictors of Persistent Anaemia in the First Year of Antiretroviral Therapy: A Retrospective Cohort Study from Goma, the Democratic Republic of Congo. PLoS One. 2015; 10(10):e0140240. PMC: 4608787. DOI: 10.1371/journal.pone.0140240. View

13.

Cao G, Wang Y, Wu Y, Jing W, Liu J, Liu M . Prevalence of anemia among people living with HIV: A systematic review and meta-analysis. EClinicalMedicine. 2022; 44:101283. PMC: 8803600. DOI: 10.1016/j.eclinm.2022.101283. View

14.

Wyatt C, Schwartz G, Ongor W, Abuya J, Abraham A, Mboku C . Estimating kidney function in HIV-infected adults in Kenya: comparison to a direct measure of glomerular filtration rate by iohexol clearance. PLoS One. 2013; 8(8):e69601. PMC: 3738577. DOI: 10.1371/journal.pone.0069601. View

15.

Petraro P, Duggan C, Spiegelman D, Hertzmark E, Makubi A, Chalamilla G . Determinants of Anemia Among Human Immunodeficiency Virus-Positive Adults at Care and Treatment Clinics in Dar es Salaam, Tanzania. Am J Trop Med Hyg. 2015; 94(2):384-92. PMC: 4751946. DOI: 10.4269/ajtmh.15-0587. View

16.

Berhane K, Karim R, Cohen M, Masri-Lavine L, Young M, Anastos K . Impact of highly active antiretroviral therapy on anemia and relationship between anemia and survival in a large cohort of HIV-infected women: Women's Interagency HIV Study. J Acquir Immune Defic Syndr. 2004; 37(2):1245-52. DOI: 10.1097/01.qai.0000134759.01684.27. View

17.

Semba R, Shah N, Klein R, Mayer K, Schuman P, Vlahov D . Prevalence and cumulative incidence of and risk factors for anemia in a multicenter cohort study of human immunodeficiency virus-infected and -uninfected women. Clin Infect Dis. 2001; 34(2):260-6. DOI: 10.1086/338151. View

18.

Harding B, Whitney B, Nance R, Crane H, Burkholder G, Moore R . Antiretroviral drug class and anaemia risk in the current treatment era among people living with HIV in the USA: a clinical cohort study. BMJ Open. 2020; 10(3):e031487. PMC: 7103836. DOI: 10.1136/bmjopen-2019-031487. View

19.

Kiragga A, Castelnuovo B, Nakanjako D, Manabe Y . Baseline severe anaemia should not preclude use of zidovudine in antiretroviral-eligible patients in resource-limited settings. J Int AIDS Soc. 2010; 13:42. PMC: 2991285. DOI: 10.1186/1758-2652-13-42. View

20.

Kerkhoff A, Wood R, Cobelens F, Gupta-Wright A, Bekker L, Lawn S . Resolution of anaemia in a cohort of HIV-infected patients with a high prevalence and incidence of tuberculosis receiving antiretroviral therapy in South Africa. BMC Infect Dis. 2014; 14:3860. PMC: 4300078. DOI: 10.1186/s12879-014-0702-1. View